Observational studyScientific reports2022

Efficacy, safety and prognostic factors in patients with refractory metastatic colorectal cancer treated with trifluridine/tipiracil plus bevacizumab in a real-world setting.

Nieves Martínez-Lago et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.